Home › Axovant Sciences - The Late Clinical Stage Biotech With Huge IPO Potential
 

Keywords :   


Axovant Sciences - The Late Clinical Stage Biotech With Huge IPO Potential

2015-06-09 21:00:38| Biotech - Topix.net

Axovant Sciences is a late-stage clinical trial biotech preparing for its initial public offering the week of June 8. The company's lead drug candidate is an Alzheimer's treatment currently in Phase 3 trials. Axovant acquired the intellectual property and rights from GlaxoSmithKline .

Tags: potential late stage huge

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Dabbagh Named General Manager of Waldencast Ventures Glaze Brand
20.05BT scraps digital landline switch deadline
20.05Essie Introduces Nail Art Studio
20.05Ilia Beauty Introduces Vegan Lip Sketch Hydrating Crayon
20.05Summer interest rate cut possible, says Bank deputy
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05Farm Progress America, May 20, 2024
More »